[Featured Stock] NKMAX Participates in World's Top Cancer Conferences Consecutively... 'Rising'

NKMAX is on the rise. It appears that the news of the company's research results being consecutively adopted by the world's top cancer conferences has had an impact.

As of 1:23 PM on the 3rd, NKMAX was trading at 13,100 KRW, up 600 KRW (4.80%) compared to the previous trading day.

On this day, NKMAX announced that its subsidiary, NKGen Biotech, will present a research abstract as a poster at the Society for Immunotherapy of Cancer (SITC) conference to be held in November in the United States. Participation in the world's top cancer conferences is the second this year, following the American Society of Clinical Oncology (ASCO) in June. The abstract adopted this time is about the anti-tumor effects of ‘HER2-CAR SNK02’ on HER2-expressing tumors.

Earlier, NKMAX successfully announced the interim results of Phase 1 clinical trials for Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) last month, demonstrating both efficacy and safety.

An NKMAX representative said, “Following the ASCO conference, we are able to present our research results at the world's most prestigious cancer conference. It will be an opportunity to share the potential and effects of the gene-unmodified autologous NK cell therapy (SNK01) as well as the off-the-shelf form of HER2-CAR SNK02.”

This content was produced with the assistance of AI translation services.